Skip to main content
Fig. 3 | Thrombosis Journal

Fig. 3

From: Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)

Fig. 3

The AUC values of edoxaban administrated at day1 (before chemotherapy initiation), day2 (after chemotherapy initiation), and day2* (after the final chemotherapy session) (n = 8). A All cases. B Cases who received 60 mg of edoxaban (n = 2). C Cases who received 30 mg of edoxaban (n = 6). Dots and error bars represent mean ± SD

Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us